Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …

Although recent clinical trials targeting amyloid-β in Alzheimer's disease have shown
promising results, there is increasing evidence suggesting that understanding alternative …

Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …

Abstract Background Prodromal Alzheimer's disease offers an opportunity to test the effect of
drugs that modify the deposition of amyloid in the brain before the onset of dementia …

Importance Positron emission tomography (PET) imaging now allows in vivo visualization of
both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau …

Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with
Alzheimer's disease (AD). Recently, we showed that abnormal levels of Aβ42 in …

Background Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ)
plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor …

Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease
mechanisms and alterations of biomarkers during the development of AD. Using cross …